Paul Frohna

Company: ImCheck Therapeutics

Job title: Chief Medical Officer

Seminars:

Maximizing the Clinical Effects of Gamma Delta T Cells: Evaluating Stand Alone & Novel Combination Therapy Approaches 2:15 pm

Considering γ9δ2 T cell-activating mAb and γ9δ2 T cell engager reliance on the endogenous pool of γ9δ2 T cells: Is there a minimum or optimal number required for successful monotherapy? Discussing the rationale for novel combination approaches being tested in the clinic to improve the therapeutic effects of a γ9δ2 T cell-activating mAb Combining of…Read more

day: Conference Day One - Afternoon Track B

Revealing Phase 2 Results of ICT01, a Gamma Delta 2 T Cell Activator, to Demonstrate Clinical Potential in Solid Tumor Settings 10:00 am

Sharing the first phase 2 data of a gamma delta 2 activator as a monotherapy and in combination with checkpoint inhibitor Identifying patient populations with clinical rationale to align with the mechanism of action to advance efficacious therapies to the clinic in the right patientsRead more

day: Conference Day One

Panel Discussion: Industry Leaders’ Year in Review: What Have We Learned This Year, & Where is the Field Heading in 2023? 8:45 am

Considering how therapeutic approaches to harness gamma delta T cells can rival alpha beta approaches Discussing how to progress to the clinic faster and attract interest from pharma companies to fund scaled trials Identifying the greatest areas of opportunity and key challenges to the industry in gamma delta T cell development Discussing the future opportunity…Read more

day: Conference Day One